Supriya K. Saha

Diamond Harbour Women's University — India

Medicine · Health Sciences

23h-index5.7kcitations97works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholangiocarcinoma and Gallbladder Cancer Studies(50), Chronic Myeloid Leukemia Treatments(16), Drug Transport and Resistance Mechanisms(15), Fibroblast Growth Factor Research(15), Colorectal Cancer Treatments and Studies(13)

Publications97 total

Nanotechnology in Triple-Negative Breast Cancer: Overcoming Drug Resistance and Tumor Aggressiveness
2025Open Access
COMPARATIVE PHYTOCHEMICAL ANALYSIS AND ANTIDIABETIC ACTIVITIES OF TENDER AND RIPENED COCONUT FRUIT PARTS
Asian Journal of Pharmaceutical and Clinical Research·2025Open Access
Comparative Anticancer Activity of Selected Medicinal Plants Highlighting Their Molecular Mechanisms
International Journal of Pharmaceutical Sciences Review and Research·2025Open Access
234 (PB222): Rational combination of pan-TEAD inhibitor SW-682 and MEK inhibitor mirdametinib in head and neck squamous cell carcinomas leads to synergistic response
European Journal of Cancer·2024· 1 cited
SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma
Science Translational Medicine·2024· 11 citedOpen Access
Figure S1 and S2 from TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Table S6 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Data from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Figure Legends, Figures S1 - S6 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Figure Legends, Figures S1 - S6 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Data from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Table S7 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Table S5 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Data from TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Table S5 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Table 1 from Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
2023Open Access
Supplementary Figures 1 - 6 from Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
2023Open Access
Supplementary Table S7 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Table S3 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Data from Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Nabeel Bardeesy(21), Andrew X. Zhu(18), Lipika Goyal(15), Vikram Deshpande(13), Genhong Cheng(12), Cristina R. Ferrone(9), Cyril H. Benes(8), David Wiese(8), Brian Zarnegar(7), Mortada S. Najem(7), Aram F. Hezel(7), Yasutaka Kato(7), Stephanie Reyes(6), David P. Ryan(6), A. John Iafrate(6), Dejan Juric(6), Katharine Yen(6), Janet E. Murphy(6), Kenneth K. Tanabe(6), Regina K. Egan(6)